Spring Newsletter 2014

In this issue: Two new research studies related to RDA published in leading journals, clinical collaborations expanded, new RnaDx lab in Sudbury.

Winter Newsletter 2014

In this issue: New research shows RDA valuable in guiding chemotherapy treatment by predicting breast cancer survivability, RnaDx’ Toronto office relocates.

Fall Newsletter 2013

In this issue: Clinical findings presented with good reception in Cremona, Italy, opportunities for RDA in UK and Germany, Dr. Sanaa Noubir joins RnaDx as Clinical Development Manager.

Summer Newsletter 2013

In this issue: Ontario multi-centre clinical trial initiated, RDA™ receives significant interest at Triple Negative Breast Cancer Conference, economic study indicates RDA™ provides healthcare cost-savings.

Fall Newsletter 2012

In this issue: Clinical trial underway, New trial planned for Teaching Hospital Network at McGill University, Clinical Research Collaboration with Instituti Ospitaliere di Cremona and updates on product development.

Spring Newsletter 2012

In this issue: Dr. Harry Bear appointed to Clinical Advisory Board, Clinical Trial Approved, Syndicated Angel Investor Round Closes, RnaDx to present at IMPAKT Breast Cancer Conference, Brussels, May 3-5

The Chemo Response Company